“Utility of Estrogen Receptor Beta and ki67 expression in Benign and Malignant Prostatic Lesions” B

Abstract

ABSTRACT Introduction – Prostate cancer accounted about 1,276,106 new cases and 358,989 deaths which is around 3.8% of deaths in men with cancer during the year 2018. The gold standard for the diagnosis of prostatic carcinoma is light microscopic findings, although there are complicated cases which would benefit from immunohistochemical studies. Recently studies have revealed the role of estrogen signaling pathways in the carcinogenesis of prostate. It is noted that there is wide variation in results of various studies regarding the expression of ER β with respect to grade of tumor in prostate carcinoma. There is need of additional research to standardize distribution of this receptor in human prostatic tissue. This will be useful in synthesizing the understanding of its role in regulation of prostate epithelial cell proliferation at various stages in lifecycle of prostate carcinoma.